Step 5: Effective Drug Treatment of HIV

Active Resources: 48

Image Library

Patient Information

Coinfection Guidelines (Hep, TB, STIs)

Articles: 10

  • Recap: 17th Ryan White HIV/AIDS Program Clinical Care Conference

    Highlights from Laura W. Cheever, MD, ScM, HRSA HIV/AIDS Bureau Associate Administrator and Conference Co-Chair

    The field of HIV/AIDS care and treatment continues to evolve rapidly. Groundbreaking developments in HIV research are regularly presented at international meetings and...

  • CROI 2017: Failure of Dolutegravir Monotherapy

    Leading up to this year, some researchers and clinicians had optimistically viewed dolutegravir an invincible ARV, a drug so mighty that it was unlikely to fail, and even more unlikely to be victim to emergent resistance mutations. Two presentations at CROI demonstrated the...

  • Efavirenz, Dolutegravir, and Darunavir: Pharmacokinetics during Pregnancy

    Three studies presented at the 2016 Conference on Retroviruses and Opportunistic Infections (CROI) explored the pharmacokinetics of antiretrovirals administered during pregnancy. These studies support the use of standard-dose efavirenz, once-daily dolutegravir, and BID ritonavir-boosted...

  • Switching from TDF/FTC to TAF/FTC

    Researchers at the 2016 Conference on Retroviruses and Opportunistic Infections presented results from a randomized double-blind, double-dummy switch study of TAF/FTC. Over 660 patients with virologic suppression on TDF/FTC-containing 3-drug regimens were either switched to TAF/FTC (200/10 mg...

  • FDA Approves New TAF-Containing Analogue of Complera; Complera Approved for Pediatrics

    The FDA has approved a single-pill combination of rilpivirine + emtricitabine + tenofovir alafenamide (TAF); its brand name is Odefsey.

    It is intended for initial treatment of HIV-1-infected persons age 12 years and older whose pretreatment HIV RNA is ≤100,000 copies/mL, or as a substitute...

  • Rilpivirine Updates: Approved for Adolescents; Possible Risk of Depression

    The U.S. Food and Drug Administration has approved rilpivirine for use in adolescents 12 to 18 years of age; it is not recommended for younger children. As in adults, it is suggested for use in ARV-naive individuals with HIV RNA levels of ≤100,000 copies/mL. The dosage is 25 mg...

  • Pyrimethamine Availability

    Pyrimethamine is no longer available in retail pharmacies in the United States, though it is available through a commercial specialty pharmacy program (the application process, approval, and delivery of the medication will take at least 2 days; for information on ordering, click...

  • Adult and Adolescent Guidelines: Major Changes

    The U.S. Department of Health and Human Services has released new treatment guidelines for adults and adolescents, and these contain some important changes. Key among these is a major shakeup in the "Recommended Regimen Options" for initial therapy. 

    Efavirenz/TDF/FTC (Atripla) has...
  • Two New Boosted-PI Coformulations

    Two boosted protease inhibitor (PI) coformulations have just been approved by the FDA. These are:

    Darunavir 800 mg + cobicistat 150 mg (Prezcobix), andAtazanavir 300 mg + cobicistat 150 mg (Evotaz)

    In these fixed-dose combinations, cobicistat is used as the pharmacokinetic booster of the PI...

  • Efavirenz Updates: Bone Mineral Density & Suicidality

    Efavirenz and Bone Mineral Density

    Persons with HIV infection have a number of risk factors for decreased bone mineral density (BMD), related not just to effects of HIV or resulting illness but also to ART. For example, BMD decreases by as much as 5-6% after initiation of ART, and certain ARVs (...

Day Title
12/2
HIV Update for Rehab Facilities and Long Term Care
12/11
HIV Medical Management: Clinical and Didactic Experience for Providers
12/15
Behavioral Health Issues in HIV Management
Day Title
11/15
Institute of Human Virology (IHV) Case Conference
10/27
Mississippi STD/HIV Clinical Update
10/23
National Day of Action to End Violence Against Women with HIV
Event type: Awareness Days
10/17
Institute of Human Virology (IHV) Case Conference
10/13
The Facts
9/28
Hepatitis C Virus: Screening, Diagnosing and Treating in Primary Care
9/26
8th Annual ANAC Conference
9/22
Southwest Alabama HIV Update
9/14
Advanced Management Issues in HIV Care
9/7
Contemporary Management of HIV
6/5
HIV Long-Term Survivors Day
Event type: Awareness Days
6/4
International Association of Providers of AIDS Care (IAPAC) International Conference on HIV Treatment Adherence
5/22
2017 National Latino HIV and Hepatitis C Conference
3/24
American Pharmacists Association Annual Meeting and Exposition 2017
3/7
Pediatric HIV/AIDS Training Course
2/13
CROI 2017: Seattle